‘Retractable Technologies Gets Australian Therapeutic Goods Administration Approval For A Single-use, Sterile Hypodermic Needle’ – Australian Gov

https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=403913&agid=(PrintDetailsPublic)&actionid=1

byHappy Mohamed

January 30, 2023

1 minute read

https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=403913&agid=(PrintDetailsPublic)&actionid=1

Savara Q2 EPS $(0.07) Up From $(0.16) YoY

By Michael Horton

Today, 9:16 PM

Savara (NASDAQ:SVRA) reported quarterly losses of $(0.07) per share. This is a 56.25 percent increase over losses of $(0.16) per share from the same period last year.

SVRA

News

KULR Technology Group Announces Uplist To NYSE American Exchange On June 7

By Benzinga Newsdesk

Today, 9:16 PM

KULR Technology Group Inc. (OTCQB:KULR) (the "Company" or "KULR"), a leading developer of next-generation lithium-ion battery safety and thermal management technologies, today announced

KULR

These Two Companies Teamed Up To ‘Become A Key Player In The Cannabis Marketing And Advertising Space’

By Vuk Zdinjak

Today, 9:16 PM

Logiq, Inc. (OTCQX: LGIQ), a global provider of e-commerce and customer acquisition solutions, entered into a strategic alliance with MediaJel, Inc., a marketing platform primarily serving regulated industries.

LGIQ

Lowe’s Expects FY22 Sales To Miss Consensus, Adds $13B To Repurchase Authorization

By Shivani Kumaresan

Today, 9:16 PM

Lowe’s Companies Inc (NYSE:LOW) reiterated its outlook for operating results for FY21 total sales to be about $95 billion, versus the…

LOW

‘Retractable Technologies Gets Australian Therapeutic Goods Administration Approval For A Single-use, Sterile Hypodermic Needle’ – Australian Gov

Related Posts

Savara Q2 EPS $(0.07) Up From $(0.16) YoY

KULR Technology Group Announces Uplist To NYSE American Exchange On June 7

These Two Companies Teamed Up To ‘Become A Key Player In The Cannabis Marketing And Advertising Space’

Lowe’s Expects FY22 Sales To Miss Consensus, Adds $13B To Repurchase Authorization